Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientific business intelligence solutions, announced the release of Discovery Studio® 2.0, the most advanced modeling and simulation software environment for drug discovery available today. The new release features a fully integrated work environment for life science researchers allowing them to go from project conception to lead optimization using a diverse set of sophisticated software applications in a single, easy-to-use environment. Because it is built upon SciTegic® Pipeline Pilot, Accelrys' scientific operating platform, Discovery Studio 2.0 is an extensible virtual discovery environment that lets researchers integrate any tool they need to create solutions that are uniquely tailored to fit their research process.
Discovery Studio 2.0 provides significant new science in the areas of rational flexible docking, activity profiling, and fragment-based design. The new fragment-based design functionality provides the opportunity to generate novel lead compounds directly from pharmacophore models and create custom pharmacophore features through an intuitive graphical interface. In addition, Discovery Studio 2.0 includes a ligand profiler that allows researchers to screen ligands against hundreds of pharmacophore models to understand potential side effects or identify targets for co-development
In the area of rational flexible docking, Discovery Studio 2.0 includes a powerful new method for docking small molecules to a receptor in which the flexibility of both the small molecules and receptor side-chains in the binding site are taken into account. This realistic approach to flexible docking is based on the well-established CHARMm engine and force field, providing a highly accurate and reliable method unique to Discovery Studio 2.0.
"Discovery Studio 2.0 represents a significant milestone in the evolution of Accelrys' life science modeling and simulation software," said Mark Emkjer, president and chief executive officer of Accelrys. "We have migrated our many legacy life science products into an integrated, easy-to-use environment that lets customers customize their workflows to suit their specific needs. Customers have been very impressed with the breadth of new science, ease of use and functionality offered in this release."
For more information about Discovery Studio 2.0 or to download a free trial of the visualization component, Discovery Studio Visualizer, please visit http://www.accelrys.com/ today.
About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Our technology and services are designed to meet the needs of today's leading research and development organizations including leading commercial, government and academic organizations. Many of the largest pharmaceutical, biotechnology, chemical, and petroleum companies worldwide use our solutions. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/
Forward-Looking Statements
This press release contains forward-looking statements. Such statements, including statements relating to Discovery Studio 2.0, including its features and potential demand therefore, are subject to risks and uncertainties including, but not limited to, the risks that Discovery Studio 2.0 will not successfully include all features described herein, or achieve market acceptance, demand relating to Discovery Studio 2.0, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
